Shortages continue


New advice on medicines shortages provided by regulators as shipping delays add another case to the list 

The TGA today advised that Prenoxad 1 mg/mL solution for injection in a pre-filled syringe is in shortage as a result of a shipping delay.

The interruption in supply began on 18 October 2018 and is not expected to be resolved until mid-November 2018.

Prenoxad 1 mg/mL solution for injection is not registered in Australia. It is supplied under section 19A of the Therapeutic Goods Act 1989 to help address a shortage of registered naloxone pre-filled syringe products, the TGA said.

Due to this, information about this shortage does not appear in the TGA’s Medicines Shortages Information Initiative, which only includes information about shortages of registered products.

The sponsor of Prenoxad, Phebra, has written to health professionals and wholesalers providing information about this shortage.

Meanwhile, ongoing shortages continue with:

  • DBL Azithromycin for injection azithromycin (as monohydrate) 500mg powder for injection vial, 
  • Metex XR metformin hydrochloride 500 mg and 100mg modified release tablet blister packs and,
  • Apotex flumazenil 0.5 mg/ 5 mL solution for injection ampoule.

The TGA has also advised that there are anticipated shortages on a range of other products including: 

  • Flumazenil-Claris flumazenil 0.5 mg/5 mL solution for injection ampoule; 
  • Atacand candesartan cilexetil 8mg tablet blister pack 
  • AstraZeneca Fentanyl 500 microgram/10mL (as citrate) injection ampoule
  • Vaniqa eflornithine hydrochloride 139mg/g cream tube
  • Repreve ropinirole (as hydrochloride) 0.25 mg tablet blister pack

Click here for more information on medicines shortages

Previous A win for pharmacy and consumers
Next ‘Pharmacy is big business’

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.